Citations

Clear

83 citation(s) found for "Shen, Win".

A real‐world experience of atrioventricular synchronous pacing with leadless ventricular pacemakers
Kowlgi, Gurukripa N. , Tseng, Andrew S. , Tempel, Nathan D., Henrich, Mark, Venkatachalam, Kalpathi L., Scott, Luis R. , Shen, Win‐Kuang , Deshmukh, Abhishek , Madhavan, Malini , Lee, Hon‐Chi, Asirvatham, Samuel J. , Friedman, Paul A. , Cha, Yong‐Mei , Mulpuru, Siva K. , Henrich, Mark J, Deshmukh, Abhishek J , Tseng, A S , Asirvatham, Samuel J , Kowlgi, Narayan G

Mayo Clinic

Journal of Cardiovascular Electrophysiology | March 2, 2022 | Volume: 33 | Issue: 5 | Pages: 982-993

10.1111/jce.15430 | PMID 35233867 Get It

AbstractAimsThe MicraTM transcatheter pacing system (TPS) (Medtronic) is the only leadless pacemaker that promotes atrioventricular (AV) synchrony via accelerometer‐based atrial sensing. Data regarding the real‐world experience with this novel system are scarce. We sought to characterize patients undergoing MicraTM‐AV implants, describe percentage AV synchrony achieved, and analyze the causes for suboptimal AV synchrony.MethodsIn this retrospective cohort study, electronic medical records from 56 consecutive patients undergoing MicraTM‐AV implants at the Mayo Clinic sites in Minnesota, Florida, and Arizona with a minimum follow‐up of 3 months were reviewed. Demographic data, comorbidities, echocardiographic data, and clinical outcomes were compared among patients with and without atrial synchronous ventricular pacing (AsVP) ≥ 70%.ResultsSixty‐five percent of patients achieved AsVP ≥ 70%. Patients with adequate AsVP had smaller body mass indices, a lower proportion of congestive heart failure, and prior cardiac surgery. Echocardiographic parameters and procedural characteristics were similar across the two groups. Active device troubleshooting was associated with higher AsVP. The likely reasons for low AsVP were small A4‐wave amplitude, high ventricular pacing burden, and inadequate device reprogramming. Importantly, in patients with low AsVP, subjective clinical worsening was not noted during follow‐up.ConclusionWith the increasing popularity of leadless pacemakers, it is paramount for device implanting teams to be familiar with common predictors of AV synchrony and troubleshooting with MicraTM‐AV devices.
A Real-world Experience of Atrioventricular Synchronous Pacing with Leadless Ventricular Pacemakers
Kowlgi, Gurukripa N. , Tempel, Nathan D., Henrich, Mark, Venkatachalam, Kalpathi L., Scott, Luis R. , Shen, Win‐Kuang , Deshmukh, Abhishek , Madhavan, Malini , Lee, Hon-Chi , Friedman, Paul A. , Cha, Yong‐Mei , Mulpuru, Siva K. , Kowlgi, Narayan G , Tseng, Andrew S. , Asirvatham, Samuel J.

Mayo Clinic

No container title available | November 16, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.163711930.05423871/v1 Get It

Aims: The MicraTM transcatheter pacing system (TPS) (Medtronic) is the only leadless pacemaker that promotes atrioventricular (AV) synchrony via accelerometer-based atrial sensing. Data regarding the real-world experience with this novel system are currently lacking. We sought to characterize patients undergoing MicraTM -AV implants, describe percentage AV synchrony achieved, and analyze the causes for suboptimal AV synchrony. Methods: In this retrospective cohort study, electronic medical records from 56 consecutive patients undergoing MicraTM -AV implants at the Mayo Clinic sites in Minnesota, Florida, and Arizona with a minimum follow-up of 3 months were reviewed. Demographic data, comorbidities, echocardiographic data, and clinical outcomes were compared among patients with and without atrial synchronous-ventricular pacing (AsVP) ≥70%. Results: Fifty-six percent of patients achieved AsVP ≥70%. Patients with adequate AsVP had smaller body mass indices, a lower proportion of congestive heart failure and pulmonary hypertension. Echocardiographic parameters and procedural characteristics were similar across the two groups. Active device troubleshooting was associated with higher AsVP. The likely reasons for low AsVP were persistent atrial arrhythmias, small A4-wave amplitude, and inadequate device reprogramming. Importantly, in patients with low AsVP, subjective clinical worsening was not noted during follow-up. Conclusion: With the increasing popularity of leadless PM, it is paramount for device implanting teams to be familiar with common predictors of AV synchrony and troubleshooting with MicraTM -AV devices.
Syncope Time Frames for Adverse Events after Emergency Department Presentation: An Individual Patient Data Meta-Analysis
Furlan, Ludovico , Trombetta, Lucia, Casazza, Giovanni , Dipaola, Franca , Furlan, Raffaello , Marta, Chiara , Numeroso, Filippo , Pérez‐Rodon, Jordi , Quinn, James , Reed, Matthew J. , Sheldon, Robert S. , Shen, Win‐Kuang , Sun, Benjamin , Solbiati, Monica , Solbiati, Monica , Dipaola, Franca , Furlan, Raffaello , Thiruganasambandamoorthy, Venkatesh , Ungar, Andrea , Costantino, Giorgio

Mayo Clinic

Medicina | November 12, 2021 | Volume: 57 | Issue: 11 | Pages: 1235

10.3390/medicina57111235 | PMID 34833453 Get It

Background and Objectives: Knowledge of the incidence and time frames of the adverse events of patients presenting syncope at the ED is essential for developing effective management strategies. The aim of the present study was to perform a meta-analysis of the incidence and time frames of adverse events of syncope patients. Materials and Methods: We combined individual patients’ data from prospective observational studies including adult patients who presented syncope at the ED. We assessed the pooled rate of adverse events at 24 h, 72 h, 7–10 days, 1 month and 1 year after ED evaluation. Results: We included nine studies that enrolled 12,269 patients. The mean age varied between 53 and 73 years, with 42% to 57% females. The pooled rate of adverse events was 5.1% (95% CI 3.4% to 7.7%) at 24 h, 7.0% (95% CI 4.9% to 9.9%) at 72 h, 8.4% (95% CI 6.2% to 11.3%) at 7–10 days, 10.3% (95% CI 7.8% to 13.3%) at 1 month and 21.3% (95% CI 15.8% to 28.0%) at 1 year. The pooled death rate was 0.2% (95% CI 0.1% to 0.5%) at 24 h, 0.3% (95% CI 0.1% to 0.7%) at 72 h, 0.5% (95% CI 0.3% to 0.9%) at 7–10 days, 1% (95% CI 0.6% to 1.7%) at 1 month and 5.9% (95% CI 4.5% to 7.7%) at 1 year. The most common adverse event was arrhythmia, for which its rate was 3.1% (95% CI 2.0% to 4.9%) at 24 h, 4.8% (95% CI 3.5% to 6.7%) at 72 h, 5.8% (95% CI 4.2% to 7.9%) at 7–10 days, 6.9% (95% CI 5.3% to 9.1%) at 1 month and 9.9% (95% CI 5.5% to 17) at 1 year. Ventricular arrhythmia was rare. Conclusions: The risk of death or life-threatening adverse event is rare in patients presenting syncope at the ED. The most common adverse events are brady and supraventricular arrhythmias, which occur during the first 3 days. Prolonged ECG monitoring in the ED in a short stay unit with ECG monitoring facilities may, therefore, be beneficial.
Abstract 1544: Early Statin Therapy Reduces Risk Of ICD Shocks In Patients With An Implantable Cardioverter-defibrillator Undergoing Ablation For Ventricular Tachycardia
Bunch, T. Jared , Friedman, Paul A. , Brady, Peter A. , Cha, Yong‐Mei , Hammill, Stephen C., Monahan, Kristi H. , Munger, Thomas M. , Rea, Robert F., Shen, Win K., Tabatabaei, Niloufar, Packer, Douglas L. , Gersh, Bernard J. , Asirvatham, Samuel J. , Jahangir, Arshad

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_320-c Get It

Background : Lipid lowering therapy reduces mortality in patients with both ischemic and nonischemic cardiomyopathies and recently has been shown to decrease ICD shocks. Radiofrequency ablation (RFA) of recurrent VT in patients with an ICD also reduces shocks following intervention. It is unclear if statin therapy after VT RFA will further impact ICD shock rates. Methods : All patients from 1993–2005 who underwent a RFA procedure for recurrent VT at the Mayo Clinic with an ICD were included. Patient records were extracted for medical and procedural details and all ICD interrogations were reviewed for VT recurrence and therapies. Results: 63 patients (age 62±15 years) were followed over 3.9±3.6 years. Comorbid diseases included: coronary artery disease 37(58%, 34 prior myocardial infarction), ARVD/C 6(10%), nonischemic dilated cardiomyopathy 7(11%), moderate-severe valve disease 14(22%), hypertension 34(54%), and hyperlipidemia 35(56%). Ejection fraction was <0.35 in 34(56%). VT was induced in all patients (LV 55 (LVOT 1), RV 8 (RVOT 3) with multiple inducible VTs in 21(33%). VT was noninducible after RFA in 39(62%) patients. Dismissal medications included: statins 19(30%), beta blockers 40(66%), ACE/ARB 37(61%), diuretics 34(55%), and digoxin 23(37%). 5-year overall survival was 63%(95% CI 55–71). Age, diabetes, and renal insufficiency were associated with increased post ablation mortality, with no medication improving survival. 5-year survival free of ICD shocks was 31%(95% CI 24–38). Only statin therapy at discharge was associated with a decreased risk of ICD shocks [5(26%) versus 26(59%), p=0.020]. 7 additional patients received statins during follow-up, but not at discharge, of these 5(71%) had shocks. Conclusion : Statin use at discharge in patients with an ICD undergoing RFA for refractory VT significantly reduced recurrent ventricular arrhythmias and ICD shocks. Although the mechanism underlying the effects of statins on arrhythmic recurrence early after RFA requires further study, these data support aggressive therapy of the underlying substrate responsible for the VT.
Abstract 4669: Does Long-QT Syndrome Involve the Sinus Node?
Němec, Jan, Buncová, Marie, Winter, Bruce, Shen, Win‐Kuang , Ackerman, Michael J. , Shusterman, Vladimir

Mayo Clinic

Circulation | July 3, 2021 | Volume: 118 | Issue: suppl_18 | Pages: No page available

10.1161/circ.118.suppl_18.s_928-b Get It

Background: The hallmark of Long QT Syndrome (LQTS) is a prolongation of the ventricular electrical action potential caused by mutations involving key cardiac ion channels on the surface membrane of ventricular myocytes. Different mutations are associated with specific modes of arrhythmia initiation and distinct changes in cardiac rhythm prior to these events. We hypothesized that some LQTS-causing mutations might involve the sinus node, leading to aberrations in cardiac rhythm. To test this hypothesis, we examined the features of cardiac rhythm in 23 genotyped patients with LQTS and 14 matched controls (C) using Holter ECG data (6hrs). Methods: QRS-complexes were identified using custom software and verified by an experienced ECG reader; series of sinus beats were extracted and gaps in time series were linearly interpolated. The mean, max, and min heart rate (HR), the time (SD, SDNN, SDANN, RMSSD, pNN50) and frequency-domain (Total (TP), Very low (VLF), Low (LF), High (HF) frequency powers, and LF/HF) indices of heart rate variability (HRV) were calculated in each 5-min interval and over the entire recording. The short-long-short irregularity was examined using the novel multiscale rhythmogenetic analysis (MRA), which quantifies changes in the HRV indices during the transition from one time-scale window to another. Results: The maximum heart rate was slower in LQTS than in C (101±13 and 119±19bpm, p=0.001). The high-frequency power (HF) was lower in LQTS than in C (80±76 and 113±58ms 2 , p<0.05). However, the short-term irregularity (quantified by the difference in RMSSD between the 75ms and 2000ms time scales) was 4 times greater in LQTS compared to C (p=0.003). Inclusion or exclusion of two patents who were on β-blockers did not change the results. Conclusions: LQTS is associated with specific changes in cardiac rhythm, including: diminished acceleration capacity, decreased high-frequency power, and enhanced short-long-short irregularity. This suggests that LQTS involves channel modifications in the sinus node, which might contribute to arrhythmogenesis. Rhythm characterization in genetic sub-types of LQTS might improve arrhythmia risk stratification in this heterogeneous patient population.
Influence of Lung Volume, Fluid and Capillary Recruitment during Positional Changes and Exercise on Thoracic Impedance in Heart Failure
Kim, Chul‐Ho , Fuglestad, Matthew , Richert, Malie L Ceridon, Shen, Win‐Kuang , Johnson, Bruce D.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 27 | Issue: S1 | Pages: No page available

10.1096/fasebj.27.1_supplement.725.1 Get It

Introduction Optivol (Medtronic Inc.) thoracic impedance (ZT) provides preemptive disease status information in heart failure (HF). It remains unclear how pulmonary‐capillary blood volume (Vc), lung volume (Lvol), and interstitial fluid influence ZT. Hypothesis Positional change and exercise result in increased Vc and/or lung interstitial fluid and ZT tracks fluctuation in these variables. Methods 12 HF patients (age 63±8yr, LVEF 41±14%) were recruited. Measures were taken at rest, exercise, recovery. This included: spirometry, ZT, diffusing capacity of the lungs for CO and NO (DLCO, DLNO), alveolar‐capillary conductance (Dm, interstitial fluid index), and Vc. Inspiratory capacity was obtained to provide consistent lung volumes for assessing ZT. Results Positional change (upright‐supine) resulted in an increased ZT (5±4%, p<0.01), while the change in Lvol (RV‐TLC) resulted in a 7±2 ohm swing in ZT (0.2±0.1ohm change/100ml change in Lvol). After 30min supine, Vc increased 28±39% (p<0.05) while Dm/Vc and Lvol decreased (29±11% and 17±3%, p<0.05). During exercise compared to baseline, Vc increased 56±44% (p<0.01), DmCO/Vc decreased 25±7% (p<0.05), and ZT did not change. During recovery measures normalized except DmCO/Vc. Conclusion Positional changes and fluctuations in Lvol influence ZT yet measures of lung fluid minimally impact this measure despite significant fluctuations.
Does the Age of Sudden Cardiac Death in Family Members Matter in Brugada Syndrome?
Kewcharoen, Jakrin , Kanitsoraphan, Chanavuth , Barry, Timothy , Shanbhag, Anusha , Ko, Nway L. Ko, Vutthikraivit, Wasawat , Home, Madhurima , Agasthi, Pradyumna , Ashraf, Hasan , Shen, Win‐Kuang , Ko Ko, Nway L, Kewcharoen, Jakrin , Kanitsoraphan, Chanavuth , Rattanawong, Pattara , Ashraf, Hasan , Shimizu, Wataru

Mayo Clinic

Journal of the American Heart Association | May 20, 2021 | Volume: 10 | Issue: 11 | Pages: No page available

10.1161/jaha.120.019788 | PMID 34013737 Get It

Background Brugada syndrome is an inherited cardiac channelopathy associated with major arrhythmic events (MAEs). The presence of a positive family history of sudden cardiac death (SCD) as a risk predictor of MAE remains controversial. We aimed to examine the association between family history of SCD and MAEs stratified by age of SCD with a systematic review and meta‐analysis. Methods and Results We searched the databases of MEDLINE and EMBASE from January 1992 to January 2020. Data from each study were combined using the random‐effects model. Fitted metaregression was performed to evaluate the association between the age of SCD in families and the risk of MAE. Twenty‐two studies from 2004 to 2019 were included in this meta‐analysis involving 3386 patients with Brugada syndrome. The overall family history of SCD was not associated with increased risk of MAE in Brugada syndrome (pooled odds ratio [OR], 1.11; 95% CI, 0.82–1.51; P =0.489, I 2 =45.0%). However, a history of SCD in family members of age younger than 40 years of age did increase the risk of MAE by ≈2‐fold (pooled OR, 2.03; 95% CI, 1.11–3.73; P =0.022, I 2 =0.0%). When stratified by the age of cut point at 50, 45, 40, and 35 years old, a history of SCD in younger family member was significantly associated with a higher risk of MAE (pooled OR, 0.49, 1.30, 1.51, and 2.97, respectively; P =0.046). Conclusions A history of SCD among family members of age younger than 40 years was associated with a higher risk of MAE.
Abstract 15321: Complications of Drug Challenge Testing in Brugada Syndrome: A Systematic Review and Meta-analysis
Vutthikraivit, Wasawat , Hooke, Patrick, Shen, Win K., Sorajja, Dan , Rattanawong, Pattara , Kewcharoen, Jakrin , Srivathsan, Komandoor

Mayo Clinic

Circulation | May 10, 2021 | Volume: 142 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.142.suppl_3.15321 Get It

Introduction: Drug challenge testing is performed to unmask Type-1 Brugada pattern. The safety and prevalence of its complications during the test are unclear. We aimed to assess the relation of complications in patients with positive and negative results by a systematic review and meta-analysis. Hypothesis: The prevalence of arrhythmic complications is higher in patients with positive drug challenge testing. Methods: We comprehensively searched the databases of MEDLINE and EMBASE from inception to June 2020. Included studies were cohort studies that reported ventricular arrhythmia that required interventions (VAI) (sustained ventricular tachycardia [VT], polymorphic VT, ventricular fibrillation, appropriate implantable cardioverter defibrillator [ICD] shock, or sudden cardiac arrest) and ventricular arrhythmias that did not required interventions (VANI) (premature ventricular complexes and non-sustained VT) during drug challenge testing. Data were combined using the random-effects model. Results: Thirteen studies involving 2,688 patients (62.7% positive) were included. The overall prevalence of VAI and VANI were 3.7% (95% confidence interval [CI]: 1.8-5.7) and 0.5% (95% CI: 0.1-0.9), respectively. VAI were more common in positive when compared to negative test result patients (1.5% [95% CI: 0.6-2.4] and 0%, respectively) but the prevalence of VANI were similar (2.7% [95% CI: 0.8-4.6] and 2.6% [95% CI: 0.8-4.6], respectively). VAI in positive result patients were more common with flecainide followed by pilsicainide and ajmaline (2.4% [95% CI: -4.3 to 9.2], 2.2% [95% CI: 0.5-4.0], and 1.5% [95% CI: 0.6 to 2.4], respectively). Most of patients with VAI during drug challenge testing underwent ICD implantation (94%). VAI during drug challenge testing in positive result patients carries an increased risk of VAI during 8.6 ± 4.9 years follow-up (odds ratio 3.73, 95% CI: 1.77-7.86, p=0.001). Conclusions: VAI were more common in patients with positive drug challenge testing, more often occurring with positive flecainide challenge, and carries an increased risk of VAI over long-term follow-up in patients with positive drug challenge testing.
Liposomal bupivacaine during subcutaneous implantable cardioverter defibrillator implantation for pain management
Lee, Justin Z. , Glasgow, Amy E. , Habermann, Elizabeth B. , Scott, Luis R. , Shen, Win‐Kuang , Kusumoto, Fred , Goel, Vasudha , Kaginele, Pranita , Cha, Yong‐Mei , Friedman, Paul A. , Asirvatham, Samuel J. , Mulpuru, Siva K. , Glasgow, Amy E. , Kusumoto, Fred M , Cha, Yong-Mei , Friedman, Paul A , Asirvatham, Samuel J , Habermann, Elizabeth , Glasgow, Amy E , McLeod, Christopher J.

Mayo Clinic

Pacing and Clinical Electrophysiology | January 25, 2021 | Volume: 44 | Issue: 3 | Pages: 513-518

10.1111/pace.14175 | PMID 33494121 Get It

AbstractBackgroundThe subcutaneous implantable cardioverter‐defibrillator (S‐ICD) has a larger generator and its implantation involves more dissection and tunneling compared to traditional transvenous defibrillator system. Liposomal bupivacaine, an extended‐release bupivacaine with 72 h of duration has been used for postoperative pain management in patients undergoing S‐ICD implantation. Our aim was to compare postoperative pain and opioid prescription patterns among patients undergoing S‐ICD implantation who received intraprocedural liposomal bupivacaine and those who did not.MethodsWe performed a retrospective analysis of all patients who underwent subcutaneous ICD implantation from January 1, 2013 to March 30, 2018 at the Mayo Clinic in Rochester, Minnesota. Patients were categorized into those who received liposomal bupivacaine and those who did not. Data on inpatient pain score, outpatient opioid prescription rates at discharge, and doses based on oral morphine equivalents (OME) were collected.ResultsA total of 104 patients underwent S‐ICD implantation. Intraprocedural liposomal bupivacaine was used in 69% of patients. Patients who received intraprocedural liposomal bupivacaine had similar mean inpatient pain scores (2.9 vs. 2.9, p = .786). There was also no difference in the rate of inpatient opioid administration (79.2% vs. 87.5%, p = .4139), outpatient opioid prescription (23.6% vs. 12.5%, p = .29), or mean OME (41.7‐mg vs. 16.6‐mg, p = .188) when comparing patients those who received intraprocedural liposomal bupivacaine and those who did not.ConclusionIntraprocedural liposomal bupivacaine administration was not associated with any significant impact on postoperative pain scores, inpatient opioid administration, and outpatient opioid prescription rates or OME amounts at discharge.
Guidance on Short‐Term Management of Atrial Fibrillation in Coronavirus Disease 2019
Rattanawong, Pattara , Shen, Win K., Masry, Hicham El , Sorajja, Dan , Srivathsan, Komandoor , Valverde, Arturo M. , Scott, Luis R. , Shen, Win, El Masry, Hicham, Valverde, Arturo, Rattanawong, Pattara , El Masry, Hicham , Srivathsan, Komandoor , Valverde, Arturo M

Mayo Clinic

Journal of the American Heart Association | June 9, 2020 | Volume: 9 | Issue: 14 | Pages: No page available

10.1161/jaha.120.017529 | PMID 32515253 Get It

Abstract Atrial fibrillation is a common clinical manifestation in hospitalized patients with coronavirus disease 2019 (COVID‐19). Medications used to treat atrial fibrillation, such as antiarrhythmic drugs and anticoagulants, may have significant drug interactions with emerging COVID‐19 treatments. Common unintended nontherapeutic target effects of COVID‐19 treatment include potassium channel blockade, cytochrome P 450 isoenzyme inhibition or activation, and P‐glycoprotein inhibition. Drug‐drug interactions with antiarrhythmic drugs and anticoagulants in these patients may lead to significant bradycardia, ventricular arrhythmias, or severe bleeding. It is important for clinicians to be aware of these interactions, drug metabolism changes, and clinical consequences when choosing antiarrhythmic drugs and anticoagulants for COVID‐19 patients with atrial fibrillation. The objective of this review is to provide a practical guide for clinicians who are managing COVID‐19 patients with concomitant atrial fibrillation.